Risk Prediction in Type II Diabetics With Ischemic Heart Disease
Launched by THEBIOSIGNALS.COM · Aug 22, 2011
Trial Information
Current as of June 25, 2025
Unknown status
Keywords
ClinConnect Summary
In patients with type 2-diabetes and ischemic heart disease autonomic function might be seriously affected.
In the present study, markers of cardiac autonomic dysfunction, repolarization and respiration abnormalities will be assessed from Holter recordings and 30-minute recordings of high-resolution three dimensional ECG, non-invasive arterial blood pressure and respiratory activity.
The correlation between markers of cardiac autonomic dysfunction and markers of severity of type-2 diabetes will be assessed. Autonomic dysfunction is assumed present when both heart rate turbulence and decel...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • type-2 diabetes
- • coronary artery disease
- Exclusion Criteria:
- • age \>80 years
- • acute coronary syndrome
- • life expectancy \<1 year
- • unable to give informed consent
About Thebiosignals.Com
The Biosignals is a pioneering clinical trial sponsor dedicated to advancing healthcare through innovative research and technology. With a strong emphasis on harnessing biosignal data, the organization specializes in developing and conducting clinical studies that aim to improve patient outcomes and contribute to the understanding of various medical conditions. By leveraging cutting-edge methodologies and a collaborative approach, The Biosignals is committed to delivering high-quality, reliable results that facilitate the development of novel therapies and enhance clinical practice. Their expertise in biosignal analysis positions them at the forefront of clinical research, driving progress in the healthcare industry.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tübingen, , Germany
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials